Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

ClinicalTrials.gov ID: NCT04018027

Public ClinicalTrials.gov record NCT04018027. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Adult Subjects With Atopic Dermatitis

Study identification

NCT ID
NCT04018027
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Cara Therapeutics, Inc.
Industry
Enrollment
401 participants

Conditions and interventions

Interventions

  • difelikefalin 0.25 mg Drug
  • difelikefalin 0.5 mg Drug
  • difelikefalin 1.0 mg Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 28, 2019
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021
Last update posted
Apr 3, 2022

2019 – 2021

United States locations

U.S. sites
38
U.S. states
20
U.S. cities
34
Facility City State ZIP Site status
Cara Therapeutics Study Site Anniston Alabama 36207
Cara Therapeutics Study Site Birmingham Alabama 35209
Cara Therapeutics Study Site Scottsdale Arizona 85254
Cara Therapeutics Study Site Bryant Arkansas 72022
Cara Therapeutics Study Site Fountain Valley California 92708
Cara Therapeutics Study Site Lomita California 90717
Cara Therapeutics Study Site Cromwell Connecticut 06416
Cara Therapeutics Study Site Farmington Connecticut 06030
Cara Therapeutics Study Site Aventura Florida 33180
Cara Therapeutics Study Site 2 Miami Florida 33125
Cara Therapeutics Study Site Miami Florida 33174
Cara Therapeutics Study Site Miami Lakes Florida 33014
Cara Therapeutics Study Site Ocala Florida 34470
Cara Therapeutics Study Site Sarasota Florida 34239
Cara Therapeutics Study Site Sweetwater Florida 33172
Cara Therapeutics Study Site Columbus Georgia 31904
Cara Therapeutics Study Site Boise Idaho 83704
Cara Therapeutics Study Site 2 Boise Idaho 83713
Cara Therapeutics Study Site Baton Rouge Louisiana 70809
Cara Therapeutics Study Site Metairie Louisiana 70006
Cara Therapeutics Study Site New Orleans Louisiana 70115
Cara Therapeutics Study Site Brighton Massachusetts 02135
Cara Therapeutics Study Site 2 Las Vegas Nevada 89119
Cara Therapeutics Study Site Berlin New Jersey 08009
Cara Therapeutics Study Site Horseheads New York 14845
Cara Therapeutics Study Site New York New York 10016
Cara Therapeutics Study Site New York New York 10023
Cara Therapeutics Study Site Cleveland Ohio 44122
Cara Therapeutics Study Site Oklahoma City Oklahoma 73118
Cara Therapeutics Study Site Tulsa Oklahoma 74136
Cara Therapeutics Study Site Medford Oregon 97504
Cara Therapeutics Study Site Rapid City South Dakota 57702
Cara Therapeutics Study Site 2 Austin Texas 78745
Cara Therapeutics Study Site Austin Texas 78759
Cara Therapeutics Study Site Cypress Texas 77433
Cara Therapeutics Study Site Dallas Texas 75225
Cara Therapeutics Study Site Salt Lake City Utah 84117
Cara Therapeutics Study Site Richmond Virginia 23226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04018027, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2022 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04018027 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →